Trajectories of Cognitive Decline Before and After New-onset Hypertension

Qingmei Chen; Jianye Dong; GC Chen; Haibin Li; Yueping Shen; Jianian Hua

doi:10.1101/2024.08.03.24311456

Abstract

Background Hypertension is a known factor for cognitive impairment, especially in midlife. However, whether the cognitive function declines before and shortly after new-onset hypertension remains largely unknown.

Objectives We aimed to examine the cognitive trajectories before and after new-onset hypertension among community-dwelling midlife and older participants.

Methods This study included 2,964 participants from the English Longitudinal Study of Ageing who were free of hypertension at baseline. Participants who had a stroke at baseline or during follow-up were excluded. Global cognition (a summary of semantic fluency, orientation, and memory) was assessed at baseline (wave 2, 2004) and at least once from wave 3 to wave 9 (2018). New-onset hypertension was defined by self-reported doctor diagnosis, use of antihypertensive medications, and blood measurements < 140/90 mmHg.

Results Over a median follow-up of 13.6 years, 1,121 (37.8%) participants developed hypertension. The cognitive decline rate among those who later developed hypertension during the pre-hypertension period was similar to the rate among those who remained hypertension-free throughout the study. After the onset of hypertension, the rate of cognitive decline accelerated in global cognition (β, −0.015 SD/year; 95% CI, −0.026 to −0.003; p=0.011), semantic fluency (β, −0.015 SD/year; 95% CI, −0.027 to −0.003; p=0.017), and memory (β, −0.022 SD/year; 95% CI, −0.033 to −0.010; p<0.001), but not in orientation ability (β, −0.012 SD/year; 95% CI, −0.028 to 0.005; p=0.157). Participants who developed hypertension in older age did not experience a reduced impact of post-hypertension cognitive decline compared to those who developed hypertension in midlife.

Conclusions Participants experienced accelerated cognitive decline upon developing new-onset hypertension. Older participants are equally susceptible to cognitive impairment due to hypertension. Early antihypertensive initiation is crucial in both midlife and later life to protect cognitive health.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the National Natural Science Foundation of China (Project No. 82202819, Qingmei Chen) and the Suzhou Science and Technology Planning Project (SKY2022123, Qingmei Chen).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This work used data from English Longitudinal Study of Ageing (ELSA). It is available to public. We applied and download data from https://www.elsa-project.ac.uk.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes